Cargando…

Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice

Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors, including cardiovascular and renal protection. However, uptake rates of these drugs remain low in patients with T2D, particularly in subpopulations most likely to b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khunti, Kamlesh, Jabbour, Serge, Cos, Xavier, Mudaliar, Sunder, Mende, Christian, Bonaca, Marc, Fioretto, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313799/ https://www.ncbi.nlm.nih.gov/pubmed/35238129 http://dx.doi.org/10.1111/dom.14684

Ejemplares similares

Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study
por: Vlacho, Bogdan, et al.
Publicado: (2021)

Changing the diabetes treatment paradigm from glucose control to cardiorenal protection
por: Ekanayake, Preethika, et al.
Publicado: (2021)

Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors
por: Jabbour, Serge A., et al.
Publicado: (2022)

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
por: Mudaliar, Sunder, et al.
Publicado: (2012)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review
por: Seidu, Samuel, et al.
Publicado: (2021)

The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond
por: Mudaliar, Sunder
Publicado: (2023)

Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2022)

Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
por: Seidu, Samuel, et al.
Publicado: (2021)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
por: Sargeant, Jack Alistair, et al.
Publicado: (2019)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol
por: Hussein, Humaira, et al.
Publicado: (2018)

Barriers to Uptake of Insulin Technologies and Novel Solutions
por: Pauley, Meghan E, et al.
Publicado: (2021)

Sodium-Glucose Transporter-2 (SGLT2; SLC5A2) Enhances Cellular Uptake of Aminoglycosides
por: Jiang, Meiyan, et al.
Publicado: (2014)

Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
por: Idris, Iskandar, et al.
Publicado: (2022)

Identification of barriers to insulin therapy and approaches to overcoming them
por: Russell‐Jones, David, et al.
Publicado: (2017)

Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
por: Idris, Iskandar, et al.
Publicado: (2021)

Effects of 6-Shogaol on Glucose Uptake and Intestinal Barrier Integrity in Caco-2 Cells
por: Jiao, Wenya, et al.
Publicado: (2023)

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
por: Polidori, David, et al.
Publicado: (2013)

Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
por: Khunti, Sachin, et al.
Publicado: (2019)

Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions
por: Kelly, Timothy D., et al.
Publicado: (2022)

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes
por: Ciaraldi, Theodore P., et al.
Publicado: (2016)

A Systematic Review of Behaviour Change Techniques within Interventions to Increase Vaccine Uptake among Ethnic Minority Populations
por: Ekezie, Winifred, et al.
Publicado: (2023)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios
por: McGill, Margaret, et al.
Publicado: (2016)

The Prevalence of Depression in White-European and South-Asian People with Impaired Glucose Regulation and Screen-Detected Type 2 Diabetes Mellitus
por: Aujla, Navneet, et al.
Publicado: (2009)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Adipose tissue from subjects with type 2 diabetes exhibits impaired capillary formation in response to GROα: involvement of MMPs-2 and -9
por: Amir Levy, Yifat, et al.
Publicado: (2022)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2021)

Cardiovascular risk profiles and the uptake of the NHS Healthcheck programme in male prisoners in six UK prisons: an observational cross-sectional survey
por: Packham, Christopher, et al.
Publicado: (2020)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Dietary Recommendations for the Prevention of Type 2 diabetes: What Are They Based on?
por: Carter, Patrice, et al.
Publicado: (2012)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
por: Davies, Melanie, et al.
Publicado: (2016)

Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals
por: Chudasama, Yogini V., et al.
Publicado: (2020)

Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance: A randomized controlled trial
por: Yates, Thomas, et al.
Publicado: (2009)

Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes
por: Edwardson, Charlotte L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4qvjug7l969n35pbpvpmb0cp4a